Osteal Therapeutics Closes $23M Series C Financing
Financing led by Asteroid Partners with new investor Gideon Strategic Partners and returning investors Johnson…
News
Osteal Therapeutics Closes $23M Series C Financing
Financing led by Asteroid Partners with new investor Gideon Strategic Partners and returning investors Johnson…
Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million
NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE…
Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million
NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE…
Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ET ISELIN, N.J.,…
Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ET ISELIN, N.J.,…
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a…
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a…
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor…
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor…
Revolo Biotherapeutics Announces the Completion of Phase 1 Multiple Ascending Dose Clinical Trial of ‘1104
The positive safety profile supports dosing of ‘1104 at higher doses in upcoming Phase 2b…
Revolo Biotherapeutics Announces the Completion of Phase 1 Multiple Ascending Dose Clinical Trial of ‘1104
The positive safety profile supports dosing of ‘1104 at higher doses in upcoming Phase 2b…
electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference
ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference
ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b…
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b…
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment…
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment…
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis”…
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis”…